Jennison Associates’s Heron Therapeutics HRTX Stock Holding History

Jennison Associates’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-229,626	Closed	-$5.96M	–	659
2018 Q4	$5.96M	Buy	229,626 +2,575	+1%	+$70.8K	0.01%	474
2018 Q3	$7.19M	Buy	227,051 +2,051	+0.9%	+$76.4K	0.01%	491
2018 Q2	$8.74M	Buy	+225,000	New	+$7.16M	0.01%	481

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Jennison Associates's HRTX Position: Q1 2019 in Review

Jennison Associates sold out of Heron Therapeutics (HRTX) in Q1 2019, closing a stake of 229,626 shares — an estimated $5.96M sold.

Jennison Associates first reported a position in HRTX in Q2 2018 and held it in 3 quarters. The position peaked at $8.74M in Q2 2018. 198 funds tracked by Wall St. Rank hold HRTX as of Q1 2019.

Jennison Associates reported no remaining Heron Therapeutics position as of Q1 2019 after selling out during the quarter.
Jennison Associates sold 229,626 Heron Therapeutics shares in Q1 2019, an estimated $5.96M.
Jennison Associates first reported a position in Heron Therapeutics in Q2 2018 and held it in 3 quarters.
Jennison Associates's Heron Therapeutics position peaked at $8.74M in Q2 2018.
198 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2019.

Based on Jennison Associates's 13F filing for Q1 2019, filed 10 May 2019.